London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Never known it so quiet, hopefully acne study out soon.
It’s ironic that I subscribed to this web site recently and after reading this article and considering opinion on the future of UK stocks (which pension funds have stopped investing in) and the future for Aim (down 50% since 2021) and the near impossibility of funding I have sold up most of my Aim holdings. When the overall direction is overwhelmingly down, it doesn’t make sense to me to continue trading on Aim. That there have only been 10 AIM IPOs so far this year tells me the market is broken. It costs around £200k in RNS etc just to stay on Aim. I’m still holding on SBTX (but not adding) and URAH (main market and recently raised twice at around the SP).
It is not specific to SBTX, but it provides details of the board's predicament. Some people may not appreciate it, but they will!
OPEN SOURCE
https://open.substack.com/pub/smallcompanychampion/p/londons-capital-conundrum?r=398wvs&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true
Hello Martinu
I am not well versed in such matters either but the RNS implies a direct relationship between macquarie and the purchasers, I assume they agree a price between them.
'Long term shareholders, including Tyndall Investement Management who have invested in the Company since IPO, have agreed to purchase the shares directly from Macquarie Bank.'
Yes Madabout, there is something to be said for the facility to be almost halfway done in this timeframe. I’m pleased about it. I’d like to know how SA feels about it and if it influences his next moves on removing the company from the CLN which they have acknowledged the market reacted badly to. Well, I think we know it will have influenced things in that it will make it easier for SA to deal out of the agreement. I’ll look forward to asking about it at the next IMC presentation.
Why would Macquarie sell at the conversion price? They want an upside surely? The very large trade the other day was at 9p so they would have made 2.5p per share margin and Tyndall get a large block of shares to add to their already significant holding below market price. The good news is that the newly released shares now sit in long term holders hands and the facility is almost halfway done in under 3 months.
Nick, as someone who is not well versed in such matters, I was wondering about such questions. Are Macq able to transfer direct to, eg Tyndall ? (Recall, Tyndall weren't the only participator). If this direct transfer is possible, would Tyndall and others have wanted a price closer to 6.5p.
I know my input will not be appreciated as I am apparently a troll. If macquarie exercise their options and sell to Tyndall my understanding is they can do that 'off market' is that correct? If so the buys/sells are not anything to do with Macquarie. Also if all the large transactions are Macquarie selling to Tyndall why not the same price?
IMHO,
The 12 preferential clients would have formulated the lysate into their brands and will have produced the marketing and advertising for when Croda launches the ingredient. These cosmetic giants will compete to be first to market. We then can monitor the reception of the product, which I believe will be marketed very rapidly.
Once again, which part of the RNS last week do you not understand? The shares are converted by Macquarie and then bought by long term holders. Tyndall were specifically named which means this intent would have to be proven to the authorities before that statement could be released. Now you start to see the transfers coming through (and they may not all be on massive blocks) and you’re off scaremongering yet again. Time for the filter methinks.
Belgrano, i was aksed to so i will apologise for some of my comments to you the otherday. It was explained to me that you are not the devious crook i accused you of. I can see you are genuine with your misreading of specific events as you have done again today. Sorry for the abuse.
Al, you're wrong again! I explained it to you yesterday. These are the shares bought by Tyndall at a premium to what Macquarie converted at. Nice gig if you can get it. Apply logic, my friend.
Although I got abuse over my thoughts that stock would be offloaded, and made a strong case it most certainly does appear that I was correct. Another 2 million share sell just came through coupled with some other still hefty ones.
Or a CEO perhaps....
Quite right. We should not be spending money developing new scientific discoveries but monetarising our existing science and proving up what we have. The Dermatonics founder has said that the key to past and future growth is the scientific evidence behind the product. This is the reason Modi are investing heavily in marketing our products. We are better off investing in product development through a leading university rather than paying for a Scientific Officer.
I used to work in academia. Many academics are employed full-time at their universities but also maintain other commitments that are time-consuming, or have other commercial roles. It also depends upon how her university apportions her employment. Often external commitments, if they are linked to the subject you are employed within are classed as part of the 1/3 research requirement of the standard academic employment contract.
Oleric, we have the science that Cath invented and we have enough going on along with future opportunities to probably last us a lifetime. So if you want to argue about semantics, fill ya boots but its a moot point. Shall we monetise the opportunities we have currently, which are many, before worrying about new science we may need in another 20 or 30 years time!
Madabout...I clearly read RNSs better than yourself.The one in question states she has stepped down from her role as CSO and returned FULL TIME to academia.I would put to you Sir that "Cath has gone" would be an accurate description of the situation.
Maybe you think "she has not gone" would be a more accurate description.
Elric's attempt to turn a bad thing[ ie Cath leaving ]into a good thing is of course totally ridiculous which is exactly what I would expect from him
Mad, There is a case to argue that SBTX has retained Cath for longer than she desired. I had a conversation with SOH years ago; we discussed her role as a CEO, and SOH said she would be stepping down when he finds a suitable replacement with commercial savvy. He declared her desire to return to academia because that's her passion. He said he would like to keep her in a similar position because of its importance.
The fact that SBTX has retained access and her passion for the lab coat and not the expense of a fur coat speak volumes, and of course, it saves SBTX a bundle of cash. Of course, some of the projects mentioned are drawing to a conclusion. Therefore, the timing makes perfect sense, but don't expect everyone without an agenda to see this for what it is.
Cath is the inventor of the Axisbiotix products and the Skinbiotix / Croda products both of those technologies are being commercialised now. There are also 3 live microbiome projects running with the university of Manchester and she is leading one of them (Inflammation, Oral and Epiderm). She returned to her full time role at the university and is still the scientific advisor to the company. She was always part time and has simply reduced her time with the company. Do you actually read any of the RNS that are released?
I bought into this company because of its wonderful science led by the trustworthy Cath.I was impressed with it entering the microbiome space as I have studied the microbiome and its relationship with the gut for years.It is clearly the next big thing in medical practice.
Now!..Cath has gone and we are putting our hopes and dreams into Heel Balm!!! Who would have thought it?
I'd guess so if they are utilising all 1200 sales clients, which suggests they are not aiming for a progressive launch.
Dermatonics Once Heel Balm - Treatment For Anhydrotic, Fissured, and Callused Hard Foot Skin - Apply Just Once a Day - It is Suitable For Diabetics - 200 ml
Brand: Dermatonics
4.6 4.6 out of 5 stars 1,074 ratings
SAR164.73
Import Charges Included
FREE delivery Saturday, 27 April. Order within 9 hrs. Details
Or fastest delivery Thursday, 25 April. Details
Delivering to Riyadh - Update location
https://www.amazon.sa/Dermatonics-Once-Heel-Balm-Anhydrotic/dp/B0773NHQ3Z/ref=lp_67929466031_1_6?pf_rd_p=0f3afb84-e9a2-4b42-9a8e-4a8362f2a679&pf_rd_r=P480XRWW3TAFFJ40VKSS&sbo=RZvfv%2F%2FHxDF%2BO5021pAnSA%3D%3D&th=1
Yes Toyin technically t hey have it it currently involve s training the sales team, the sales team engaging with their clients to gain an understanding of demand at which point a RNS with a forecast will be issued and the products will be shipped supported by a high profile marketing campaign
Aquae, they have already launched.